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Summary 
Two-dimensional gel electrophoresis of in vitro phosphorylated proteins coprecipitated by CD2 
monoclonal antibody (mAb) from Brij58 lysates of resting human T lymphocytes and natural 
killer (NK) cells resulted in the identification of a novel 29/30-kD disulfide-linked dimer (pp29/30). 
Comparative two-dimensional analysis of CD2, CD3, CD4, CD5, and CD8 immunoprecipitates 
revealed that pp29/30 associates with these signaling receptor complexes but not with CD18, 
CD27, and CD29 in human T lymphocytes. Analysis of CD2 immunoprecipitates prepared from 
T  cell antigen receptor/CD3-modulated T  lymphocytes indicated that pp29/30 preferentially 
associates  and comodulates with the human T  cell antigen receptor (TCR).  Since tyrosine 
phosphorylated pp29/30 selectively interacts with the Src homology type 2 domains (SHZ) of 
the protein tyrosine kinases  p561ok and p59fr  n but not ZAP70 the present data suggest that 
pp29/30 represents a novel signaling receptor associated phosphoprotein likely involved in the 
activation of human T  lymphocytes and NK cells. 
T 
he primary signal that initiates human T cell activation 
is delivered through the interaction of the TCR with 
its natural ligand, antigen/MHC. The TCR is composed of 
disulfide-linked polymorphic heterodimers (or~3, ~//~) that 
noncovalently associate with the CD3 molecules (CD3-% 
-/~, -e) as well as with ~" chains (1-5). Whereas the individual 
components of CD3 are only expressed as single chain poly- 
peptides in T lymphocytes, ~'chains are expressed as disulfide- 
linked homodimers that associate with the TCR/CD3 com- 
plex in T lymphocytes and the CD16 molecule in NK cells 
(6,  7). 
The earliest biochemical events after external binding of 
antigen/MHC to the to the TCR are activations  of protein 
tyrosine kinases  that induce tyrosine phosphorylation of a 
number of intracellular proteins (8). The major candidates 
for these protein tyrosine kinases are members of the src family 
(p56  lCk and p59%) (9, 10) as well as the recently cloned syk- 
related kinase ZAP70 (11, 12). Since neither the TCR nor 
the CD3/~" complex possess intrinsic tyrosine kinase activity, 
it was postulated that the TCR/CD3/~" complex associates 
physically with protein tyrosine kinases. Such a view is sup- 
ported by the recent observations that the CD3 molecules 
associate noncovalently with p59% (13) whereas phosphor- 
ylated ~" chains associate with ZAP70 (11, 12,  14). 
With regard to the signaling function of the TCR/CD3/~" 
complex, CD3-e and ~" chains are of particular interest since 
both molecules alone are capable of transmitting external 
signals into the intracellular environment independent of ex- 
pression of CD3-y and CD3-6 (15, 16). This applies to acti- 
vation of the tyrosine kinase pathway as well as to further 
downstream events, e.g., lymphokine secretion. A short pep- 
tide motif (Y-xx-L-x(6-8)-Y-xx-L)  present in the cytoplasmic 
domains of both CD3-e and -~" has been defined which seems 
to be relevant for the triggering capacity of these molecules 
(17). 
Besides the TCtL/CD3/~-mefliatefl  primary signal,  sec- 
ondary stimuli are required for resting T cells to become fully 
activated (18). Such secondary signals result from interactions 
of accessory receptors (e.g.,  CD2,  CD4, CD5,  CD8,  and 
CD28) with their respective ligands (e.g., CD58/CD2, MHC 
class II/CD4, CD72/CD5, MHC class I/CD8, and CD80/ 
CD28)  (19-23).  How  accessory receptors transduce their 
signals into the intracellular environment is as yet poorly un- 
derstood. Since the intracytoplasmic domains of accessory mol- 
ecules do not bear sequence similarities  to typical signaling 
receptors it has been proposed that they, like the TCR, transmit 
signals via noncovalently associated molecules. 
In this regard the recent demonstration that the CD2, CD4, 
CD5, and CD8 coreceptors associate with the protein tyro- 
sine kinases p561ok  and p59~ as well as with CD3-e and the 
CD3-associated portion of ~" (24-29) was of particular im- 
portance. Moreover, coexpression of CD2 and at least ~" ap- 
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The latter observations for the first time provided a molec- 
ular basis for the known CD2 unresponsiveness of experimen- 
tally anergized T  lymphocytes that  lack expression of the 
TCR/CD3  molecular complex (31). 
Employing two-dimensional  analysis  of in vitro-labeled 
immunoprecipitations, we here describe a novel dimeric phos- 
phoprotein, pp29/30, that coprecipitates with the CD2, CD4, 
CD5, and CD8 accessory receptor complexes as well as with 
the TCR/CD3  complex under mild detergent  conditions. 
Comparative analysis of immunoprecipitates  obtained from 
untreated and TCR/CD3-modulated T lymphocytes revealed 
that pp29/30 preferentially associates  and apparently comodu- 
lates with  the CD3  molecular complex. 
Materials and Methods 
Cells.  Resting  human  T  lymphocytes were prepared  from 
heparinized whole blood of healthy donors as described (32). To 
induce modulation of the TCR/CD3 complex, 2  x  106 freshly 
prepared T  lymphocytes/ml were cultured for 18 h at 37~  and 
100% humidity in a tissue culture supernatant of anti-CD3-e mAb 
2Ad2A2 (28)  (IgM,  kindly provided by Dr. E. Reinherz, Dana 
Farber Cancer Institute, Boston, MA). The HPB-ALL cell line was 
maintained in tLPMI 1640 supplemented with 10% FCS, 2% Gluta- 
mine, and 1% Penicillin-Streptomycin  (all from Gibco, Eggenstein, 
Germany). The human NK clone 7408 was propagated as described 
(33), It expresses the TCR-~/gene in germline configuration (33) 
and mRNA for CD3-e and CD3-/~ but no mRNA  for CD3-% 
It expresses the CD56 (NKH1) antigen and is unreactive with mAbs 
directed at the TCR, the CD3-e molecule as well as CD4 and CD8, 
respectively. 
mAbs, Antisera, and Ghtathione S-transferase (GST)  1 Fusion Pro- 
teins.  Protein A purified mAbs employed for primary CD2 and 
CD3 immunoprecipitates were CD2 mAb ICRFCD2.1.1A (IgG2a 
[32]) and CD3 mAb OKT3 (IgG2a; Ortho, Neckargemfind, Ger- 
many). Other mAbs used for immunoprecipitation experiments 
were obtained through the Fourth (Vienna, Austria, 1989) and Fifth 
(Boston, MA, 1993) International Conference On Haman Leuco- 
cyte Differentiation Antigens and were as follows: CD5 (M-T505), 
CD18 (BA12), CD29 (K20), and CD27 (MT271). The latter mAbs 
were used at a 1:500 vol/vol dilution in immunoprecipitation ex- 
periments.  Antisera used for reprecipitation  experiments were: anti- 
p56  lck (kindly provided by Dr. A. Veillette, McGill Cancer Center, 
McGill University, Montreal, Canada [28, 34]), anti-p56 fyn (a gift 
from Dr. Sarah Courtneidge, European Molecular Biology Labo- 
ratory, Heidelberg, Germany [28]), anti-~" (donated by Dr. Doreen 
Cantrell, Imperial Cancer Research Fund, London, UK [28, 35]), 
and anti-pp32 (directed at the first  10 NH2-terminal amino acids 
of the human pp32 molecule [34].  GST fusion proteins of com- 
plete or, alternatively,  isolated src homology type 2 (SH2) domains 
of p561ok, p59  fy", ZAP70 (NH2  +  COOH-terminal),  and p75  'yk 
(COOH-terminal) were prepared and purified as described (36). 
Immunoprecipitation, In Vitro Kinase Reaction, and Reprecipitation 
Experiments.  107  lymphocytes/sample  were  harvested,  washed 
once in ice-cold TBS, and then lysed for I h in ice-cold lysis buffer 
(28) supplemented with 1% Brij58 detergent (Pierce, Oud Beijer- 
land, The Netherlands). In general, antigens were immunoprecip- 
1Abbreviations used in  this paper: GST, glutathione  S-transferase; IEF, 
isoelectric  focusing;  LPC, L-ce-lysophosphatidylcholine;  PI., isoelectric  point; 
SH2, src homology type 2. 
itated from postnuclear cell lysates employing 25/zl of  packed CNBr 
Sepharose beads coupled with protein A purified mAbs. The im- 
munoprecipitates  shown  in  Fig.  3  were  prepared  in  96-well 
microtiterplates. Briefly, plates were precoated over night at 4~ 
with 100/~1 polyclonal goat anti-mouse antiserum (1:400 vol/vol 
in PBS; Dianova, Hamburg, Germany). Plates were washed three 
times with PBS/1% BSA (Sigma Chemical Co., St. Louis, MO) 
and blocked for 2 h with 200 #1 of PBS/BSA. Subsequently 100 
#1 mAb diluted 1:500 vol/vol in PBS/BSA was added to each well 
and incubated for at least  1 h.  Plates  were washed again  with 
PBS/BSA and 100 ttl of cell lysate corresponding to 2  x  106 T 
cells was added to each well and incubated at 4~  for 1 h. Plates 
were washed four times and then subjected to in vitro kinase assay. 
In vitro kinase reaction of the washed immunoprecipitates, elution 
of coprecipitated proteins employing 1% Triton X-100 lysis buffer, 
and reprecipitation experiments were essentially performed as pre- 
viously described (28, 34). Reprecipitation experiments employing 
GST  fusion  proteins  were  performed  with  25  #1  of packed 
glutathion-agarose coupled GST fusion proteins. 
Biotinylation Experiments and Nonreducing/Reducing SDS-PAGE. 
Before biotinylation, 5  x  107 cells were washed twice in PBS and 
resuspended in 1 ml of ice cold PBS. 50/xl of a 1-mg/ml solution 
of r-o~-lysophosphatidylcholine  (LPC; Sigma Chemical Co.) in ice- 
cold ethanol was added to the cell suspension,  mixed, and allowed 
to incubate for 5 min at 4~  Subsequently cells were pelleted for 
I rain at 2,500 rpm and washed twice in ice cold PBS. Permeabi- 
lized cells were resuspended in 250/xl of a biotinylation solution 
that consisted of 2.5 mg/ml sulfo-NHS-LC-biotin (Pierce) in PBS. 
LPC-treated cells were labeled with biotin for 10 min at room tem- 
perature. Subsequently 1 ml of ice-cold culture medium was added 
and incubated for further 2 min to quench unbound biotin. Bio- 
tinylated cells were washed twice in PBS, lysed in Brij58 containing 
lysis buffer, and immunoprecipitated as above with the exception 
that 50/xl of packed beads were employed for immunoprecipitation. 
After immunoprecipitation,  beads were washed as above, and precipi- 
tated proteins released from the beads in 30 #1 Triton X-100 lysis 
buffer supplemented with 8 M urea for 10 min at 37~  Subse- 
quently beads were spun down, the supernatant aspirated, and 6 #1 
of 5  x  SDS-sample buffer was added.  The solution was then sub- 
jected to a 6.3-cm-long tube gel (a 5.3-cm long 12% SDS-gel and 
a 1-cm-long stacking gel) casted in a 1.5-mm diameter glas tube. 
The tube gel was run with 80 V until the dye front had reached 
the bottom of the glas tube, equilibrated in 1  x  reducing SDS- 
sample buffer for 45 min at room temperature and layered on top 
of a second 1.5-ram-thick  12%  mini-SDS slab gel.  The second 
dimension was also run at 80 V until the dye front had reached 
the bottom of the gel. Proteins were electrophoretically transferred 
to nitrocellulose sheets (Amersham, Braunschweig, Germany) using 
a semidry blotting apparatus (Pharmacia) and the blots were blocked 
over night in TBS supplemented with 5% nonfat dried milk. Blots 
were incubated with a  1:3,000  vol/vol dilution of biotin/strep- 
tavidin/peroxidase-complex  (Amersham)  in  TBS/0.2%  Tween 
20/5%  milk for 1 h  at room temperature and then washed for 
four times with TBS/0.2% Tween 20. Biotinylated proteins were 
subsequently detected using  the Amersham  chemiluminescence 
(ECL) detection system. 
Two-dimensional Gel Electrophoresis.  In vitro phosphorylated pro- 
teins were eluted from primary or secondary immunoprecipitates 
for 10 min at 37~  in 50/A of 1% Triton X-100 lysis buffer sup- 
plemented with 8 M urea (Gibco) +  50 mM dithiothreitol (Sigma 
Chemical Co.). Subsequently beads were spun down and the su- 
pernatant loaded on isoelectric focusing (IEF) tube gels. When im- 
munoprecipitates were prepared in 96-well microtiterplates, 25 #1 
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proteins. IEF and two-dimensional SDS-PAGE was performed as 
described (37) with the exception that the two-dimensional SDS- 
PAGE was prerun for 8 h in SDS-running  buffer supplemented  with 
thioglycolic acid (1:2,500 vol/vol dilution; Sigma Chemical Co.). 
The position of radiolabeled proteins was determined by autoradio- 
graphy of the dried gels. 
Results 
Identification of  Novel CD2-associated  Phosphoproteins by Means 
of Two-dimensional Gel E/ectrophoresis.  To identify proteins 
that copurify with the human CD2 molecule under mild de- 
tergent conditions, in vitro kinase assays of primary CD2 
immunoprecipitates obtained from Brij58 lysates of resting 
human T  lymphocytes were performed. The pattern of in 
vitro phosphorylated proteins was subsequently analyzed by 
means of two-dimensional gel electrophoresis with IEF in 
the first  dimension followed by reducing 10%  SDS-PAGE 
in the second dimension. 
Fig. 1,/eft shows that at least nine distinct proteins coprecipi- 
rate with CD2 under these experimental conditions. These 
include a series of distinct spots migrating at 18-20 kD and 
20-22 kD, respectively. Additional phosphoproteins migrate 
at, respectively,  29,  30,  32,  56,  59,  68,  and 85  kD.  Phos- 
phoamino acid analysis of the different spots revealed  that 
all proteins are exclusively phosphorylated on tyrosine residues 
(data not shown). 
To identify the proteins shown in Fig.  1,  /eft, a primary 
CD2 immunoprecipitate was obtained from Brij 58 lysates 
of resting human T  lymphocytes and subjected to in vitro 
kinase assay. After kinase reaction, phosphoproteins were eluted 
from the CD2 immunoprecipitate employing Triton X-100 
lysis buffer.  The released material was then incubated with 
individual polyclonal rabbit antipeptide sera or mouse mAb 
directed at known signaling molecules expressed in human 
Figure  1.  Analysis  and identification  of in vitro-labeled  phosphoproteins  that coprecipitate  with CD2 mAb under mild detergent conditions. (Left) 
In vitro kinase  assays  were performed  on CD2 immunoprecipitates  obtained  from  Brij58 lysates  of resting human  T lymphocytes.  After  kinase  reaction, 
phosphorylated proteins were eluted from the CD2 immunoprecipitates  and subjected to two-dimensional  gel electrophoresis with IEF in the first 
dimension  followed  by reducing  10% SDS-PAGE  in the second  dimension.  (Right)  Identification  of the phosphoproteins  shown  left  by means  of  reprecipi- 
tation experiments. In vitro-labeled  phosphoproteins  coprecipitated  by CD2 mAb were released  from the primary  CD2 immunoprecipitate  employing 
lysis  buffer  supplemented  with 1% Triton  X-100. Released  proteins were then resubjected  to secondary  immunoprecipitations  employing  the following 
mouse mAb and polyclonal  antipeptide sera: (A) anti-~'; (B) anti-CD3-e; (C) anti-pp32; (D) anti-CDS; (E) anti-p561ck; and (F) anti-p59~  'n. The sec- 
ondary immunoprecipitates  were analyzed  on two-dimensional  gels as described for the left  panel. 
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onto protein A-Sepharose beads, eluted with 8 M  urea and 
subsequently analyzed by means of two-dimensional gel elec- 
trophoresis  as above. 
Fig. 1, right, panels A  and B demonstrates that the 18-20- 
kD spots and the 20-22-kD spots represent in vitro-labeled 
~" chains (Fig.  1,  right,  panel A) and CD3-e  (Fig.  1,  right, 
panel B), respectively. The acidic 32-kD spot coprecipitated 
by CD2 mAb specifically reacts with an antipeptide serum 
directed at the CD45-associated phosphoprotein pp32 (Fig. 
1,  right,  panel C) (34).  The diffusely focused material at 68 
kD was specifically reprecipitated by CD5 mAb (Fig. 1, right, 
panel D) while the 56- and 59-kD spots were identified as 
p56  lck and p59  fyn (Fig.  1,  right,  panels E  and F).  Two spots 
could not be identified, namely a 29/30-kD protein (pp29/30) 
as well as an acidic 85-kD phosphoprotein (see question marks 
in Fig.  1,  left). 
Fig.  1, right,  panel F shows that the 85-kD protein (p85) 
was selectively reprecipitated by an antiserum directed at the 
p59  frD protein tyrosine kinase (upper arrow in Fig.  1, right, 
panel F). Preliminary experiments indicate that p85 represents 
a single chain polypeptide that is constitutively phosphorylated 
on  tyrosine residues  and  selectively associates  with  p59  r 
(data not shown). 
As shown in Fig. 2, pp29/30 represents the reduced com- 
ponent of a 58-60-kD  disulfide linked dimer.  Thus,  when 
an in vitro-labeled primary CD2 immunoprecipitate obtained 
from Brij58 lysates of resting human T lymphocytes was ana- 
lyzed on two-dimensional gels under nonreducing conditions 
(Fig.  2 B), pp29/30  was no longer detectable (note the ex- 
pected shift of the 18-kD ~'-monomer to the 36-kD dimeric 
form under nonreducing conditions).  Since the molecular 
weight of reduced pp29/30  was approximately half that of 
p56  lck and, moreover, its isoelectric point (PI.) almost exactly 
matched the PI.  of p56  lck (5.3), we reasoned that pp29/30 
comigrates with in vitro-labeled p561ok under nonreducing 
conditions. To prove this point, spots I and 2 shown in Fig. 
2, A and B, were excised and resubjected to one-dimensional 
reducing 10% SDS-PAGE.  As shown in Fig.  2 C, pp29/30 
was recovered from spot 2 (but not spot 1) when reanalyzed 
under reducing conditions.  Identical results were obtained 
when the immunoprecipitates were prepared from cells lysed 
in presence of up to 20 mM iodoacetamide, which rules out 
the possibility that dimerization ofpp29/30 is due to a post- 
lyrical artifact (not shown). 
Previous data had shown that the protein tyrosine kinases 
p56  lck and p59~,  CD3-~, and ~" chains copurify with the ac- 
cessory receptor molecules CD2,  CD4,  CD5,  and CD8  as 
well as the TCR/CD3 complex in Brij lysates of  rat and human 
T lymphocytes (24-29). It was therefore important to inves- 
tigate whether pp29/30 copurifies also with these receptors. 
As shown in Fig. 3, @ht,  in vitro-phosphorylated pp29/30 
was detectable in CD3, CD4, CD5, and CD8 immunoprecipi- 
tares obtained from Brij58 lysates of HPB-ALL cells. (Note 
that similar results were obtained when the immunoprecipi- 
tates were prepared from resting human T  lymphocytes or 
PHA-activated T  cells,  not shown). Although the relative 
intensities of the various phosphorylated protein spots differed 
among the respective immunoprecipitates (compare, for ex- 
ample,  the  relative intensities  of the protein  spots  corre- 
sponding to CD3-e and ~" chains in Fig. 3 B, to CD5 in Fig. 
3 D  and to pp32 in Fig.  3 F), pp29/30  is clearly present in 
all these immunoprecipitates with the exception of the CD45 
immunoprecipitate. 
The identity of the 29/30-kD proteins coprecipitated by 
CD3, CD4, CD5, and CD8 mAbs as pp29/30 was confirmed 
by peptide map analysis as well as analysis of the above im- 
munoprecipitates by nonreducing two-dimensional gel elec- 
trophoresis where the 29/30-kD  spots migrated at  58  kD 
(not shown). In vitro kinase assays of  control goat anti-mouse, 
CD18, CD27, and CD29 immunoprecipitates did not result 
in detectable phosphoproteins (Fig. 3, left, lanes I-3,  and 9). 
Figure 2.  pp29/30  represents  a disulfide  linked  dimer. 
Two-dimensional  analysis  of  an in vitro-labeled  CD2 im- 
munoprecipitate  under either (A) reducing  or, (B) non- 
reducing  conditions.  (C) Reanalysis  of  spots 1 and 2 shown 
in A and B by means of reducing the one-dimensional 
SDS-PAGE.  CD2 immunoprecipitates  were  obtained  from 
resting human T lymphocytes  lysed in 1% Brij58. 
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CD3, CD4, CDS, and CD8 signaling receptor 
complexes. (Left) One-dimensional analysis of 
in  vitro  kinase  assays performed  on  goat 
anti-mouse (lane 1), CD29 (lane 2), CD18 (lane 
3), CD2 (lane 4), CD3 (lane 5), CD4 (lane 6), 
CD8 (lane 7), CD45 (lane 8), and CD27 (lane 
9) immunoprecipitates prepare] from Brij58 ly- 
sates  of  HPB-ALL  cells.  (Right)  Two- 
dimensional analysis of in vitro-labeled goat 
anti-mouse (A), CD3 (B), CD4 (C), CD5 (D), 
CD8 (E), and CD45 (F) immunoprecipitates 
prepared from Bdj58 lysates of HBP-ALL cells. 
The position of in vitro-labeled  pp29/30 is in- 
dicated by an arrow. Positions corresponding 
to in vitro-labeled  CD3-e and ~, CD5 and pp32 
are indicated by triangles in B, D, and F, respec- 
tively. 
These data indicate  that  pp29/30,  associates  with the fig- 
naling receptors CD2, CD3, CD4, CD5, and CD8 in human 
T  lymphocytes. 
We have recently  reported  that  CD3-e  and ~" chains  are 
undetectable  in  CD2  immunoprecipitates  obtained  from 
TCR/CD3-modulated  T lymphocytes because  the proteins 
comodulate with  the TCR/CD3  complex  (28).  We were 
next interested  to  investigate  whether  a  similar  behavior 
would be true for pp29/30.  Thus, freshly prepared human 
T  lymphocytes  were  incubated overnight  in  the  presence 
of an anti-CD3-e mAb of the IgM isotype known to induce 
modulation of the TCR/CD3  molecular  complex (28, 31). 
Subsequently,  two-dimensional gel electrophoresis  was per- 
formed on in vitro-labeled  CD2 immunoprecipitates obtained 
from Brij58  lysates of untreated  vs.  TCR/CD3-modulated 
cells. 
Fig. 4 A  shows the known IEF pattern of in vitro-labeled 
polypeptides  coprecipitated  by CD2  mAb  from  untreated 
human T lymphocytes lysed in Brij58. The positions and den- 
sitometric  analyses of the pp29/30  and pp32 protein spots 
Figure  4.  Impaired in  vitro phos- 
phorylation of pp29/30  in CD2  im- 
munoprecipitates  prepared from TCR/ 
CD3-modulated T  cells. Two-dimen- 
sional analysis of an  in vitro-labeled 
CD2 immunoprecipitate obtained from 
resting (A) or TCR/CD3-modulated 
(/3) human T lymphocytes. Cells were 
lysed in 1% Brij58. Numbers above the 
protein  spots  indicate the  integrated 
densities of p29/30 and pp32 as judged 
from densitometric analysis. The de- 
creased in vitro phosphorylation of the 
unknown 100-kD spot shown in B was 
not consistently observed and, therefore, 
was considered as nonspecific. 
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two-dimensional analysis  of a CD2 immunoprecipitate ob- 
tained from TCR/CD3-modulated T lymphocytes shown in 
Fig. 4 B revealed the previously reported loss of ~" chains and 
CD3-e in the CD2 immunoprecipitate (28).  Perhaps more 
importantly in vitro-phosphorylation of pp29/30  was also 
strongly reduced (41 arbitrary units  =  97% reduction com- 
pared to the nonmodulated cells)  in CD2 immunoprecipi- 
tates obtained from CD3/TCR modulated cells. In contrast, 
the integrated density of pp32 rather increased (629 arbitrary 
units). 
This finding suggested that pp29/30,  like CD3-e and -~', 
comodulates with the CD3/TCR complex. To exclude the 
possibility that reduced in vitro phosphorylation of pp29/30 
in the CD2  immunoprecipitate obtained from TCR/CD3 
modulated cells is due to comodulation/inhibition of a pro- 
tein tyrosine kinase that is responsible for phosphorylation 
of pp20/30  rather than to comodulation of pp29/30  itself, 
we determined the amounts of pp29/30  protein coprecipi- 
tated by CD2 mAb from untreated vs. TCR/CD3  modu- 
lated T  lymphocytes. 
Since pp29/30 is not detectable in immunoprecipitates ob- 
tained from externally 125I- or biotin-labeled T  lymphocytes 
(not shown), we permeabilized T  cells with LPC followed 
by biotinylation. CD2 and CD3 immunoprecipitations were 
subsequently obtained from untreated and TCR/CD3 modu- 
lated T lymphocytes and analyzed by two-dimensional non- 
reducing/reducing  SDS-PAGE.  The  latter  technique  was 
chosen because analysis of the biotinylated immunoprecipi- 
rates by IEF/SDS page suffered from too high background. 
The data shown in Fig. 5, right, panels A  and C indicate 
that biotinylated off-diagonal 29/30 kD spots are visible  in 
CD3 and to a fivefold lesser extent in CD2 immunoprecipi- 
tates obtained from untreated human T lymphocytes. In ad- 
dition, a biotinylated 16-kD off-diagonal spot corresponding 
to ~" is coprecipitated by CD2 and CD3 mAbs, respectively. 
The 29/30 kD spot was proven to represent pp29/30 by (a) 
its comigration with a 29/30-kD  off-diagonal spot released 
from an in vitro y-[32p]ATP-labeled  CD2 immunoprecipitate 
(Fig. 5,/eft); (b) the observation that the in vitro-labeled off- 
diagonal 29/30  kD spot shown in Fig.  5,  left produced an 
identical V8 protease peptide pattern as in vitro y-[32p]ATP- 
labeled pp29/30 separated on two-dimensional IEF/PAGE gels 
as above, and (c) the finding that the in vitro-labeled 29/30- 
kD spot shown in Fig. 5, left runs at exactly the same posi- 
tion  as  in  vitro y-[3zp]ATP-labeled pp29/30  when reana- 
lyzed on two-dimensional IEF/PAGE (not  shown). 
Importantly, when the CD2 immunoprecipitate was pre- 
pared from TCR/CD3-modulated T  lymphocytes and ana- 
lyzed by Western blotting  (Fig.  5,  right, panel D), both  ~" 
and pp29/30 were no longer observed. (Note that very low 
amounts of pp29/30  were detectable in the CD2 immuno- 
precipitate upon prolonged exposure of the shown gel.) Similar 
results were obtained when CD4 immunoprecipitates were 
prepared from untreated and TCR/CD3-modulated cells and 
analyzed on nonreducing/reducing SDS-PAGE. However, the 
amounts of biotinylated pp29/30 coprecipitated by CD4 mAb 
were approximately four times lower than in case of CD2. 
Note  that  the  loss  of pp29/30  in  CD2  (and  CD4)  im- 
munoprecipitates obtained from TCR/CD3 modulated cells 
was specifically due to TCR/CD3  modulation and not the 
result of altered reactivity of the mAbs with their respective 
antigens since the amounts of p56  lck and pp32 coprecipitated 
by  CD2  and  CD4  mAb  did  not  differ in  untreated  and 
TCR/CD3-modulated cells as judged from reanalysis of the 
shown blots employing anti-p56  lck and anti-pp32 rabbit an- 
tisera (not shown).  Collectively, the data shown in Fig.  5 
strongly suggest that pp29/30  preferentially associates  and 
comodulates with the TCR/CD3  complex. 
Pp29/30 Is Expressed and Coprecipitates with CD2 in NK 
Cells.  Given that pp29/30 comodulates with the TCR/CD3 
complex, we were interested in proving whether expression 
of the molecule is restricted to TCR/CD3 expressing T lym- 
phocytes. To this end we performed in vitro kinase assays 
of CD2 immunoprecipitates obtained from Brij 58 lysates of 
the TCR/CD3-negative NK clone 7408 (33). The data shown 
in  Fig.  6  D  demonstrate  that  pp29/30  is  expressed  and 
copurifies with CD2 in the NK done. Since CD3-E mAb 
did not coprecipitate detectable material from clone 7408 (Fig. 
6 B) one can exclude the possibility that coprecipitation of 
Figure 5.  Evidence  that pp29/30 comodulates  with 
the TCR/CD3 molecular  complex.  (Left)  Analysis  of 
an in vitro-labded CD2 immunoprecipitate  on two- 
dimensional  nonreducing/reducing  gel electrophoresis. 
The identity  of the individual  in vitro  phosphorylated 
spots is indicated.  (Right)  Loss ofbiotinylated  pp29/30 
in CD2 immunoprecipitates  prepared  from  TCR/CD3 
modulated  T cells. CD3 (A and B) and CD2 (C and 
D) immunoprecipitates  were  obtained  from  untreated 
(A and C) or TCR/CD3-modulated  (B and D) T lym- 
phocytes that had been permeabilized  with LPC be- 
fore biotinylation and lysis in Brij58 detergent. Bi- 
otinylated  molecules  coprecipitated  by CD2 and CD3 
mAbs were  blotted onto nitrocellulose  and detected 
with the ECL chemiluminescence  system. 
902  A Novel Signaling Receptor-associated  Phosphoprotein Figure 6.  Expression  and CD2 association of pp29/30 in Brij 58 lysates of NK cells. In vitro kinase assays of CD3 (A and B) or CD2 (C and 
D) immunoprecipitates  were obtained from Brij 58 lysates of either HPB-ALL (A and C) or NK clone 7408 (B and D) and analyzed  by means of 
two-dimensional  gel electrophoresis.  Note the coimmunoprecipitation  and in vitro  phosphorylation  of ~"  chains  by CD2 mAb in the NK clone  (solid  triangle). 
pp29/30 by CD2 mAb was due to contaminating CD3 posi- 
tive  feeder  cells.  The  identity  of  the  29/30-kD  protein 
coprecipitated by CD2  and CD3 mAb from HPB-ALL as 
well as the NK clone with pp29/30  was confirmed (a) by 
V8 protease peptide map analysis  of the individual 29/30- 
kD spots; and (b) analysis of the individual CD2 and CD3 
immunoprecipitates under nonreducing conditions where the 
protein migrated at  58-60  kD  (not shown). 
In Vitro-labeled pp29/30 Interacts with the SH2 Domains of 
p56  ~k and p59fy".  As demonstrated in Fig.  1, panel 2 boxes 
E and F, anti-p56  lCk and p59~  antisera both coprecipitated 
low amounts of in vitro-labeled pp29/30  (arrow in Fig.  1, 
right, panel E and lower arrow in Fig. 1, right, and F). Since 
this was clearly not the case in primary p56  l~k and p59~ im- 
munoprecipitates obtained under identical experimental con- 
ditions (e.g., Triton X-100 lysis buffer, not shown), we rea- 
soned that in its tyrosine phosphorylated state pp29/30 acquires 
the capacity to interact with p56  lck and p59~  most likely 
through binding to  the SH2-domains of the kinases (36). 
To  investigate  this  possibility,  in  vitro-labeled  phos- 
phoproteins eluted from a primary CD2 immunoprecipitate 
obtained from Brij58 lysates of HPB-ALL were resubjected 
to immunoprecipitation employing GST fusion proteins of 
intact p56  l~k, p59~,  and ZAP70 coupled to  agarose beads 
or, alternatively,  GST fusion proteins of  isolated SH2 domains 
of p56 lck, p59  fyn, ZAP70,  and p72sy  k. 
Fig. 7 demonstrates that in vitro-labeled pp29/30  and ~" 
chains were specifically reprecipitated by either intact GST- 
p56  lck and GST-p59  fyn fusion proteins or, alternatively, iso- 
lated  GST-SH2  domains  of the p56  l~k  and  p59fy" protein 
tyrosine kinases. In marked contrast, intact GST-ZAP70 and 
GST-SH2-ZAP70 fusion proteins selectively reprecipitated ~" 
chains but not pp29/30.  The same was true for the GST- 
SH2-p72sy  k fusion protein.  The identity of the 29/30-kD 
spots shown in Fig.  7 as pp29/30  was proven by means of 
peptide map analysis and nonreducing IEF (not shown). Col- 
lectively, these data indicate that  tyrosine phosphorylated 
pp29/30 interacts with the SH2 domains of p56 lCk and p59 fyn 
but  not of ZAP70 and p72 syk. 
Discussion 
Combining the sensitive technique of in vitro kinase assay 
with the resolution of two-dimensional gel electrophoresis 
we  here  identified  an  as  yet  unknown  phosphoprotein, 
pp29/30, that coprecipitates with the signaling receptors CD2, 
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mains of p56  kk and p59~. In vitro-labeled  phosphoproteins  were  released 
from a primary  CD2 immunoprecipitate  obtained  from Brij 58 lysates  of 
HPB-ALL  cells  as described  in Fig. 1. The released  phosphoproteins  were 
resubjected to  secondary  immunoprecipitation  employing the agarose 
bead-coupled  GST fusion  proteins  indicated  on top of  the individual  panels. 
Secondary immunoprecipitates  were then analyzed  by means of two- 
dimensional  gel electrophoresis.  The position of pp29/30 is indicated  by 
an  aF!eOW. 
CD3,  CD4,  CD5,  and CD8 under mild detergent condi- 
tions in human T  lymphocytes (Figs.  1 and 3). 
Analysis of in vitro-labeled pp29/30  under nonreducing 
vs.  reducing conditions (Fig.  2) revealed that the apparent 
molecular mass of the noureduced molecule is "~58-60 kD. 
This indicates that pp29/30 represents the reduced form of 
a  58-60-kD  disulfide-linked dimer.  Our  observation  that 
pp29/30  is not detectable after external labeling of T  lym- 
phocytes suggests that the protein is mainly localized intraeel- 
lularly. 
Importantly,  in  vitro  phosphorylation  of pp29/30  was 
strongly  impaired  in  immunoprecipitates  obtained  from 
TCR/CD3-modulated T lymphocytes (Fig. 4). Together with 
the finding that the amounts of biotinylated pp29/30  pro- 
tein coprecipitated by CD2 (and CD4) mAb were also strongly 
reduced in immunoprecipitates prepared from TCR/CD3- 
modulated cells (Fig.  5),  these data suggest that  pp29/30 
represents a novel protein that preferentially associates  and 
comodulates with the TCR/CD3  complex. Its presence in 
CD2, CD4, CD5, and CD8 immunoprecipitates likely results 
from coprecipitation of components of the TCR/CD3 com- 
plex with  the CD2,  CD4,  CDS,  and CD8  receptors that 
has previously been demonstrated by a number of different 
laboratories (24-29).  Our recent analysis of a large panel of 
mAbs directed at human lymphocyte  surface molecules demon- 
strated that this is a rather special feature of the above receptor 
complexes (29) and does not apply to the majority of addi- 
tional receptor molecules expressed by human T  cells. 
Although pp29/30 preferentially associates and comodu- 
lates  with TCR/CD3,  the protein is clearly distinct from 
the known  components  of the  CD3  molecular complex, 
CD3-3,,  CD3-~, CD3-~, and CD3-w as well as ~"  chains. Thus, 
pp29/30 is not reprecipitated by mAbs or antisera directed 
at either CD3-3,,  CD3-E,  or ~" chains (Fig.  1,  right,  panels 
A and B and data not shown). Moreover, pp29/30 is distinct 
from the CD3-3, and CD3-~ glycoproteins because it neither 
possesses N- nor O-linked carbohydrates (not shown). Fi- 
nally, the identification of pp29/30 as a dimer (Fig.  2) rules 
out the possibility that pp29/30 is identical with the recently 
described 29-kD CD3-w chain which represents a single chain 
polypeptide (38). 
A number of dimeric molecules with subunits of*30 kl~ 
have been described in human, mouse, or rat T [ymphocytes. 
These include the CD8 glycoproteius, the CD69 molecule, 
the 4-1BB antigen, the NKR-Pt glycoprotei•  as well as the 
most recently described murine p32 protein (39-42).  Although 
not shown here p29/30 is different from these molecules for 
the  following reasons:  In) pp29/30  is  exFressed in  CD8 
depleted resting human T lymphocytes and, ~  is not 
reprecipitated by CD8 mAb in CD8-positive cells;  (/P).  sev- 
eral individual CD69 mAbs failed to reprecipitate pp29/30. 
Moreover, PMA-stimulation of resting human T lymphocytes, 
which induces modulation of the TCR/CD3 molecular com- 
plex, leads to comodulation and concomitant downregula- 
tion of pp29/30,  whereas CD69 expression is upregulated 
(39).  (c) The same applies  for the recently described 4-BB1 
antigen, which also represents a PMA-inducible mouse T cell 
antigen  (40). 
We cannot yet formally exclude the possibility that pp29/30 
is homologous to the NKR-P1 or the murine p32 glycopro- 
rein (41, 42). However, these possibilities  seem unlikely since 
NKR-P1  is almost exclusively expressed in rat and mouse 
NK cells (42) and expression of p32 seems to be limited to 
murine pre-T  lymphocytes (41).  In  contrast,  pp29/30  is 
strongly expressed in mature human T lymphocytes. Finally, 
both NKR-P1 and p32 represent N-glycosylated proteins (41, 
42),  whereas pp29/30  represents  a  nonglycosylated poly- 
peptide. 
After in vitro tyrosine phosphorylation, pp29/30  is spe- 
cifically reprecipitated by the SH2 domains of the src family 
members p56 ~:k and p59fy" but not by SH2 domains of the 
src unrelated protein tyrosine kinases ZAP70 or, alternatively, 
p72sy  k (Fig.  7). Since pp29/30 is not found to be associated 
with  either p56 kk or,  alternatively,  p59~  in  primary im- 
munoprecipitates obtained from nonstimulated T  lympho- 
cytes, this indicates that pp29/30 is most likely not constitu- 
tively  phosphorylated  on  tyrosine  residues  in  resting  T 
lymphocytes in vivo and, therefore, does not bind to the SH2 
domains of the kinases. 
Although we have so far been unable to show in vivo tyro- 
sine phosphorylation and interaction of pp29/30  with  the 
SH2 domains of p56 lc~ and/or p59fy  n after CD2-  or,  alter- 
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obtained in our laboratory indicate that tyrosine-phosphor- 
ylated pp29/30 coimmunoprecipitates with the SH2 domains 
of p56  lck in pervanadate-treated T  lymphocytes (43).  Inas- 
much as pervanadate is believed  to mimic proximal T  cell 
activation events  (e.g.,  tyrosine kinase activation and tyro- 
sine phosphatase inhibition, [43]) this indicates that under 
particular conditions pp29/30 undergoes tyrosine phosphory- 
lation in vivo. 
The phosphopeptide sequences of signaling proteins that 
preferentially bind to the SH2 domains of the src protein tyro- 
sine kinases have recently been elucidated (36). Phosphopep- 
tide *YEEI (*Y indicates a phosphorylated tyrosine residue) 
represents  the motif that shows highest affinity for SH2 do- 
mains. Lower affinities were found for substitutions at *Y 
+  1  =  D, T, Q,  *Y  +  2  =  N, Y, D, Q, and*Y  +  3  = 
M, L, V. The reprecipitation of pp29/30 with the SH2 do- 
mains of p561ok and p59~ indicates that the protein sequence 
of p29/30 likely contains such motifs. 
The  biochemical properties  of pp29/30  show  striking 
similarities  to ~" chains. First, both pp29/30 and ~" represent 
nonglycosylated  dimeric molecules that preferentially associate 
and comodulate with the TCR/CD3 complex. Second,  ex- 
pression  of pp29/30 and ~" is not restricted to TCR/CD3- 
positive lymphocytes since they are also expressed in NK cells. 
Third, in their tyrosine phosphorylated state pp29/30 and 
~" specifically interact with the SH2 domains of protein tyro- 
sine kinases (p561ok, p59~, ZAP70) known to play a key role 
in human T  cell activation (9,  10). Based on these findings 
it is tempting to speculate  that pp29/30 represents a novel 
receptor-associated protein that serves a signaling function 
in human T  lymphocytes and NK cells. 
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